APC-004
45 evidence topics · 5 sources
Objective
Effect of two AD109 doses on hypoxic burden and AHI over a single night
Rationale for testing a lower atomoxetine dose in mild to low-moderate OSA
“In this trial, we studied patients with mild or low-moderate OSA (AHI between 5 and 20 events/h), as we hypothesized that this group of patients could be treated with a lower dose of the combination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Specifically, a lower dose of atomoxetine could help to reduce side effects and improve long-term tolerance in this population if the efficacy was comparable to the higher dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose finding as described by the company
Location and study date
Registered study dates and sites
| Field | Quoted record |
|---|---|
| Study start (actual) | “2020-12-22” |
| Primary completion (actual) | “2021-05-31” |
| Number of locations | “This study has 3 locations” |
| California site | “San Diego, California, United States, 92103 Pacific Research Network” |
| Georgia site | “Atlanta, Georgia, United States, 30328 NeuroTrial Research” |
| Pennsylvania site | “Philadelphia, Pennsylvania, United States, 19063 Brian Abaluck, LLC” |
Study design
Randomized, double-blind, placebo-controlled, 3-period single-dose crossover
“This study was a randomized, double-blind, placebo-controlled, 3-period, single-dose crossover study that evaluated the safety and efficacy of 2 different dose combinations of AD109 (atomoxetine plus R-oxybutynin) in participants with mild to moderate OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants who met all enrollment criteria were centrally randomized to receive the following oral treatments prior to a single night PSG, separated by at least a 1-week washout period:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Six registered treatment sequences
Standard and lower dose comparison as described by the company
Eligibility criteria
Inclusion: age, body mass index, AHI4 of 5 to 20 events/h, and symptoms
“Participants had to be between 25 and 65 years of age (inclusive) at the screening visit and have a body mass index between 18.5 and 40.0 kg/m2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The screening PSG had to demonstrate an AHI (hypopneas scoring required a 4% drop in peripheral capillary oxygen saturation [SpO2]) of 5–20 events/h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients had to also report minimal self-reported symptomatology, such as a score ≥ 1 on the Patient Global Impression of severity (PGI-S) or history of 1 or more of the following OSA symptoms: snoring or nighttime gasping/choking, daytime sleepiness, fatigue, or decreased concentration, nonrefreshing sleep, sleep fragmentation (including from nocturia), or morning headache, irritability, decreased mood or libido.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion: other sleep disorders, interacting medications, and unstable disease
“Patients could not have another active sleep disorder or be on any medication that could affect respiratory, muscle, or neurologic function.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants could also not have any other major organ system disease or unstable medical disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion: registered cardiac and CPAP criteria
Exclusion: insomnia, psychiatric, neurologic, constipation, and urinary retention criteria as described by the company
Treatment
High-dose and low-dose AD109 and placebo at bedtime
“Each received low-dose AD109 (37.5/2.5 mg), high-dose AD109 (75/2.5 mg), and placebo at bedtime across 3 overnight periods in a randomized order.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dosing of the study treatment occurred immediately prior to lights out.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aroxybutynin 2.5 mg with two atomoxetine doses
“in this trial we tested the effect of aroxybutynin, a purified version of the R-enantiomer not yet commercially available, at the dose of 2.5 mg, combined with 2 doses of atomoxetine (37.5 and 75 mg) on OSA severity in a randomized, placebo-controlled, crossover trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using hypoxic burden as the primary endpoint
Authors' rationale: hypoxic burden as a predictor of cardiovascular morbidity and mortality
“In this trial, we chose the sleep apnea-specific HB instead of the more traditional AHI as our primary outcome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HB has been recently introduced as a new metric to stratify OSA severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Analysis of such studies showed that the HB is a better predictor of the cardiovascular morbidity and mortality linked to OSA compared to AHI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hypoxic burden definition in the publication: all apneas and hypopneas regardless of desaturation
“The primary objective outcome was the HB of sleep apnea, which is calculated as the area under the curve of the baseline oxygen saturation and represents the real ventilatory deficit of the disorder as it considers the frequency, length, and the depth of the obstructive events, whereas AHI simply represents the frequency of the same events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For each apnea or hypopnea (regardless of associated desaturation), the pre-event baseline saturation was defined as the maximum SpO2 during the 100 seconds prior to the end of the event and the area under this baseline value is calculated over a subject-specific search window, which was defined individually for each study, by averaging the SpO2 curve with respect to the end of all events occurring in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The hypoxic burden was then obtained by adding these individual desaturation areas and dividing the total area by the sleep duration, with the units of hypoxic burden being (%min)/h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hypoxic burden definition in the registry: events with 4% or greater desaturation
Primary and key secondary endpoints as described by the company
Editorial comment on hypoxic burden as the primary endpoint
“The primary endpoint of hypoxic burden is a laudable choice that highlights the movement away from solely relying on AHI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further validation of this parameter is needed, but inclusion of hypoxic burden in the efficacy of new therapies is warranted and adds to the strength of the findings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other outcomes: polysomnography scoring, sleepiness, and vital signs
“Standard overnight PSGs were recorded and scored in accordance with the American Academy of Sleep Medicine scoring manual.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Effects on situational, self-reported sleepiness were assessed by the Karolinska Sleepiness Scale, administered on the morning following each PSG test.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On the following morning, blood pressure and heart rate were measured in the seated posture.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and power
“A total of 30 participants was planned to enter the 3-treatment crossover study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was planned to have 80% power to detect a treatment difference on the primary endpoint at a 2-sided 0.05 significance level, if the true difference of hypoxic burden between treatments was at least -3.7 (%min)/h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This assumed that the within-participant standard deviation was 9 and a discontinuation rate of less than 20%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants analyzed for the primary outcome in the registry
| Field | Quoted record |
|---|---|
| Enrollment (actual) | “Enrollment (Actual) 32” |
| Participants analyzed for the primary outcome, each comparison | “Overall Number of Participants Analyzed 27 27 27” |
Description of analysis sets
Statistical methods: repeated-measures model, log transformation, and three comparisons per endpoint
“In general, continuous variables were summarized by presenting medians and interquartile ranges due to the skewed distribution of most variables.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to the known logarithmic distribution of HB, the primary analysis of HB was performed also after log10 (HB + 1) transformation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Each endpoint for this study implicitly contained 3 hypothesis tests based on comparisons between study treatments: (1) 75/2.5 dose vs placebo, (2) 37.5/2.5 dose vs placebo, (3) 37.5/2.5 dose vs 75/2.5 dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A repeated-measures model was used to compare log10(HB+ 1), HB (without log-transformation), AHI, and other PSG variables between treatment arms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety analysis methods
“The analyses were descriptive and were based on the safety set.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The safety assessments were summarized by the study treatment the participant received within each period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Screening, randomization, completion, and withdrawals
“A total of 65 participants signed the informed consent form and were enrolled in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-three participants failed screening and 32 participants were randomized (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One ineligible participant was inadvertently randomized but not treated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Four participants were treated but terminated before completing the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three patients withdrew for personal reasons and one for an adverse event (severe oxygen desaturation during sleep), which raised the safety risk according to one of the study investigators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry participant flow
Completion as reported by the company
Baseline characteristics
Demographics of the safety population
“Patient median (interquartile range) age was 53 years (47 to 62) and body mass index was 30.4 kg/m2 (27.0 to 33.1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 11 female patients (35.5% of the total) and participants were mostly white (71%) and African American (23%), with the remaining patients (n = 2) having multiple ethnicities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-five (80.6%) participants were not Hispanic or Latino.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline polysomnography, median (interquartile range), AHI and ODI with 4% desaturation criterion
| Parameter | Baseline (n = 31) |
|---|---|
| Log10 (HB + 1) | “1.11 (0.76–1.32)”View highlighted excerpt for this quote |
| HB, (%min)/h | “11.8 (4.8 to 20.0)”View highlighted excerpt for this quote |
| AHI, events/h | “13.5 (8.1 to 17.0)”View highlighted excerpt for this quote |
| AHI supine, events/h | “18.6 (11.3 to 29.1)”View highlighted excerpt for this quote |
| ODI 4%, events/h | “10.0 (6.0 to 15.4)”View highlighted excerpt for this quote |
Registry baseline hypoxic burden, median (full range)
| Field | Quoted record |
|---|---|
| Hypoxic burden, (%*min)/hour | “11.8 (2.08 to 87.78)” |
| Measure description | “Hypoxic burden is a measure of the overall burden of de-oxygenation (hypoxia) due to upper airway obstructive events for every hour of sleep, measured from the SaO2 signal on the polysomnography done overnight.” |
Efficacy results
Hypoxic burden and AHI4 on a single night: high and low dose versus placebo
“Median [interquartile range] hypoxic burden for participants on placebo was 13.9[4.5–21.9] (%min)/h vs 2.3[0.1–10.5] (%min)/h for patients on the high dose (P < .001) and to 7.3[2–12.5] (%min)/h on the low dose (P < .01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Apnea-hypopnea index went from a median of 13.2[8.0–19.1] events/h on placebo reduced to 5.5[2.2 to 9.6] events/h on the high dose (P < .001) and to 7.8[4–13.7] events/h on the low dose (P < .05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Respiratory polysomnography parameters by treatment, median (interquartile range), AHI and ODI with 4% desaturation criterion
Dose response and hypoxic burden responders
“AHI and Log10(HB + 1) were also significantly improved on AD109 high dose compared to low dose, suggesting a dose-related effect size.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Note that > 70% of patients had a reduction of at least 30% in HB and > 40% of participants had a reduction in HB > 90% on high-dose AD109.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AHI4 by body position and sleep stage
“The effect on the AHI was maintained when analysis was limited to the supine position and was present in both non-rapid eye movement and rapid eye movement (REM) sleep, although the reduction in AHI did not reach statistical significance in REM (P = .12 on high dose vs placebo) probably because only 13 participants had REM on both placebo and high dose AD109, and thus the analysis lacked of statistical power.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no relationship between the reduction in REM sleep and the reduction in overall AHI for both the low dose (P = .12, r2 = 0.11) or the high dose of AD109 (P = .56, r2 = 0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry primary outcome: mean difference in hypoxic burden (95% confidence interval), events with 4% or greater desaturation
| Comparison | Log10 HB, difference in log10HB[(%*min)/h] | Raw HB, (%*min)/h |
|---|---|---|
| AD109 dose 1 (atomoxetine 75 mg) vs placebo | “-0.40 (-0.54 to -0.25)” | “-6.90 (-10.20 to -3.60)” |
| AD109 dose 2 (atomoxetine 37.5 mg) vs placebo | “-0.21 (-0.36 to -0.07)” | “-4.70 (-8.01 to -1.38)” |
| Dose 2 vs dose 1 | “0.18 (0.04 to 0.33)” | “2.20 (-1.23 to 5.36)” |
Percentage reductions in hypoxic burden and AHI4 versus placebo, as reported in the company prospectus
Health-related quality of life and patient-reported outcomes
Karolinska Sleepiness Scale the morning after dosing
“Subjectively, the proportion of nonsleepy patients, defined by a Karolinska Sleepiness Scale < 5, was 0.83 (95% confidence interval 0.69 to 0.97) on placebo, 0.93 (0.83 to 1.00) on low-dose AD109, and 0.86 (0.74 to 0.99) on high-dose AD109.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These different outcomes between treatments were not statistically significant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Treatment-emergent adverse events in at least 2 participants, safety population
Most frequent adverse events and authors' safety assessment
“The most frequently reported treatment emergent adverse effects occurring in at least 2 study participants were dry mouth (3 [9.7%] participants), decreased appetite (2 [6.5%] participants), and thirst (2 [6.5%] participants).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both high-dose AD109 and low-dose AD109 were safe and well-tolerated, without clear difference between the high and low doses or between the active doses and placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry adverse events: deaths, serious adverse events, and other adverse events at a 5% threshold
| Event | AD109 dose 1 (75 mg) | AD109 dose 2 (37.5 mg) | Placebo |
|---|---|---|---|
| All-cause mortality | “0/30 (0.00%)” | “0/28 (0.00%)” | “0/29 (0.00%)” |
| Other adverse events, total | “4/30 (13.33%)” | “2/28 (7.14%)” | “2/29 (6.90%)” |
| Dry mouth | “2/30 (6.67%)” | “1/28 (3.57%)” | “0/29 (0.00%)” |
| Decreased appetite | “2/30 (6.67%)” | “0/28 (0.00%)” | “0/29 (0.00%)” |
Sleep architecture and arousals
“As shown in Table 2, a high dose of AD109 reduced total sleep time and sleep efficiency and increased wake after sleep onset compared to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, both doses reduced REM sleep and increased N1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The high dose of AD109 reduced the respiratory arousals, but both doses increased the number of spontaneous arousals (ie, not associated with respiratory events or leg movements), so that the total number of arousals was increased on AD109 (P < .05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sleep and morning vital signs by treatment, median (interquartile range)
Study limitations
Summary
- Design: single-dose crossover with one night of polysomnography per treatment, separated by washouts of at least 1 week.
- Population: AHI4 of 5 to 20 events/h, ages 25 to 65, and BMI 18.5 to 40.0 kg/m2, with exclusion of other active sleep disorders, medications affecting respiratory, muscle, or neurologic function, and unstable medical disorders (the prospectus names a history of insomnia). The registry describes the population as mild obstructive sleep apnea, and the publication as mild or low-moderate OSA.
- Size: 32 participants were randomized, 31 were treated, and 27 were analyzed for each primary comparison in the registry.
- Hypoxic burden definition differs by source: the publication includes each apnea or hypopnea regardless of associated desaturation, and the registry includes events with 4% or greater desaturation. An accompanying editorial states that further validation of the measure is needed.
- REM analysis: only 13 participants had REM sleep on both placebo and high-dose AD109, which the authors state left the REM analysis without statistical power.
- Funding: the publication states the study was funded by Apnimed.